The GLOVe regimen, combining glofitamab, lenalidomide, and venetoclax, shows rapid and deep responses in high-risk MCL ...

Key Takeaways. TTP following R-CHOP is a strong prognostic factor for survival in R/R DLBCL, with shorter TTP linked to ...

The 2025 pharmaceutical pipeline is expanding with generics, biosimilars, and new therapies, despite delays from patent ...

The top Managed Care Cast episodes explored wellness visits, weight loss drug access, neurospine care, public health policy, ...

The future treatment landscape for follicular lymphoma is being rapidly shaped by several promising agents and novel ...

The top 5 infectious disease stories on AJMC.com this year covered both outbreaks and government-related developments. Bird ...

Remote therapeutic monitoring (RTM) of patients with blood cancers cut hospitalizations from infections by 52% over 2 years ...

Optimally positioning CD19-directed therapies in the follicular lymphoma treatment sequence requires consideration of both ...

The FDA today approved nerandomilast (Jascayd; Boehringer Ingelheim) for the treatment of progressive pulmonary fibrosis (PPF ...

“In support to recent literature in arrhythmogenic cardiomyopathy, our cohort data showed that the protective effect of a negative genetic testing on disease progression was a stronger predictor than ...

Influenza and COVID-19 are seeing an uptick in incidence as the winter months approach, making protecting vulnerable populations a high priority.

A nationwide Danish cohort study reports cardiovascular events up to 1 year after infection, comparable to that observed with influenza. A nationwide Danish cohort study reports cardiovascular events ...